Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.